Celldex Therapeutics CLDX Business Segments — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's business segments — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's business segments — research and development expense?
- Celldex Therapeutics (CLDX) reported business segments — research and development expense of $73M in Q1 2026.
- How has Celldex Therapeutics's business segments — research and development expense changed year-over-year?
- Celldex Therapeutics's business segments — research and development expense increased by 38.7% year-over-year, from $52.61M to $73M.
- What is the long-term trend for Celldex Therapeutics's business segments — research and development expense?
- Over 3 years (2022 to 2025), Celldex Therapeutics's business segments — research and development expense has grown at a 43.9% compound annual growth rate (CAGR), from $82.26M to $245.07M.
- What does business segments — research and development expense mean?
- This metric represents the total aggregate costs incurred by the company for research and development activities within its primary business segment. It encompasses all expenditures related to the discovery, clinical testing, and advancement of the company's therapeutic pipeline. Monitoring this figure is essential for assessing the company's commitment to innovation and its long-term growth potential in the biopharmaceutical sector.